Primary Biliary Cholangitis Therapeutics Market Expected to Reach $1.4 Billion by 2032

 Primary biliary cholangitis (PBC), formerly known as primary biliary cirrhosis, is a chronic autoimmune liver disease. It primarily affects the small bile ducts within the liver, causing inflammation, damage, and ultimately, the destruction of these ducts. Primary biliary cholangitis therapeutics are the medications that help to slow the progression of the disease, improve liver function, and relieve symptoms. The ursodeoxycholic acid, obeticholic acid are the U.S. Food and Drug Administration (FDA) approved drug for the treatment of primary biliary cholangitis. In cases where these medications are not effective or the disease progresses despite treatment, liver transplantation may be considered as a last resort option.

According to a new report published by Allied Market Research, titled, “Primary Biliary Cholangitis Therapeutics Market,” The primary biliary cholangitis therapeutics market size was valued at $683.95 million in 2022, and is estimated to reach $1.4 billion by 2032, growing at a CAGR of 7.1% from 2023 to 2032.

In addition, recently PPARα/PPARδ agonist, and ileal bile acid transport (IBAT) inhibitors have also evolved as effective therapeutics for the treatment of primary biliary cholangitis. The antihistamines, cholestyramine, rifampin, sertraline, and opioid antagonists are used as an adjunctive therapy to alleviate itching (pruritus) associated with primary biliary cholangitis.

Alarming rise in the in cases of primary biliary cholangitis, as well as increase in number of research regarding primary biliary cholangitis drives the growth of primary biliary cholangitis therapeutics market share. For instance, in June 2022, GSK plc presented 12 abstracts at the European Association for the Study of the Liver’s International Liver Congress 2022 in London. presence focuses of GSK on novel investigational specialty medicines, linerixibat, an ileal bile acid transporter (IBAT) inhibitor for cholestatic pruritus in primary biliary cholangitis (PBC). This year, new data is being shared in International Liver Congress, to deliver novel medicines for patients with significant unmet medical need, such as those who suffer from cholestatic pruritus in primary biliary cholangitis.

Moreover, the increase in initiatives taken by various organizatons for reducing the burden of the diseases and rise in number of clinical trials of primary biliary cholangitis therapeutics drive the growth of primary biliary cholangitis therapeutics market share. For instance, in December 2021, Cadila Healthcare Limited (Zydus Cadila) received permission from the U.S. Drug regulator, U.S. Food and Drugs Administration (USFDA) to initiate Phase 2(b)/3 clinical trials to evaluate the efficacy and the safety of Saroglitazar Magnesium in patients with primary biliary cholangitis (PBC).

Contact Us: 
 
United States 
1209 Orange Street, 
Corporation Trust Center, 
Wilmington, New Castle, 
Delaware 19801 USA. 
Int’l: +1–503–894–6022 
Toll Free: +1–800–792–5285 
Fax: +1–800–792–5285 
help@alliedmarketresearch.com